List of Excipients in Branded Drug ALECENSA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genentech Inc	ALECENSA	alectinib hydrochloride	50242-130	CARBOXYMETHYLCELLULOSE CALCIUM	2035-04-24
Genentech Inc	ALECENSA	alectinib hydrochloride	50242-130	CARNAUBA WAX	2035-04-24
Genentech Inc	ALECENSA	alectinib hydrochloride	50242-130	CARRAGEENAN	2035-04-24

ALECENSA Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Alecensa (alectinib hydrochloride) is a Roche/Genentech oral ALK inhibitor marketed in the United States as a 150 mg hard capsule. Its commercial formulation uses conventional excipients, creating opportunities for generic manufacturers and excipient suppliers in capsule-to-tablet development, bioequivalence control, supply-chain qualification, and patient-friendly dosage forms. The principal barriers are alectinib’s low aqueous solubility, food-effect management, analytical complexity, and residual patent and regulatory risk.

What is ALECENSA and how is it marketed?

Alecensa contains alectinib hydrochloride and is approved for ALK-positive non-small cell lung cancer, including metastatic disease and adjuvant treatment after tumor resection in eligible patients. The product is administered orally at 600 mg twice daily, equivalent to four 150 mg capsules per dose, with food [1].

Attribute	Alecensa profile
Active ingredient	Alectinib hydrochloride
Brand name	Alecensa
Developer and originator	Chugai Pharmaceutical; commercialized globally with Roche/Genentech
Therapeutic class	Anaplastic lymphoma kinase inhibitor
Primary indication	ALK-positive non-small cell lung cancer
U.S. dosage form	150 mg hard gelatin capsule
Recommended adult dose	600 mg orally twice daily with food
FDA initial approval	December 11, 2015
U.S. regulatory pathway	New drug application
Biosimilar pathway	Not applicable; alectinib is a small molecule
Generic pathway	Abbreviated new drug application, subject to applicable exclusivity and patent requirements

The FDA first approved Alecensa for ALK-positive metastatic NSCLC after progression on crizotinib or intolerance to crizotinib. The indication later expanded to include patients who had not previously received an ALK inhibitor and patients receiving adjuvant treatment after complete tumor resection [1].

What excipients are used in Alecensa capsules?

The U.S. label identifies a capsule formulation containing alectinib hydrochloride with lactose monohydrate, hydroxypropyl cellulose, sodium lauryl sulfate, carboxymethylcellulose calcium, and magnesium stearate. The capsule shell contains gelatin and coloring materials, including titanium dioxide and iron oxide pigments. Printing ink is also used on the capsule shell [1].

Formulation component	Function in the dosage form	Commercial significance
Lactose monohydrate	Diluent and carrier	Supports powder bulk and capsule fill uniformity
Hydroxypropyl cellulose	Binder and granulation aid	Can affect granule strength and dissolution
Sodium lauryl sulfate	Wetting or surfactant agent	Helps manage poor aqueous wetting
Carboxymethylcellulose calcium	Disintegrant	Promotes capsule-fill dispersion after shell rupture
Magnesium stearate	Lubricant	Controls ejection and manufacturing friction
Gelatin	Capsule shell material	Determines shell mechanical properties and storage behavior
Titanium dioxide and iron oxides	Colorants and opacity agents	Support product identification and brand appearance
Printing ink	Product marking	Supports traceability and anti-counterfeit controls

The excipient list does not establish the entire formulation-development strategy. Commercial manufacturers must control particle-size distribution, polymorphic form, salt form, blend uniformity, capsule-fill weight, dissolution, degradation products, and food-state performance.

Why does alectinib create excipient-development opportunities?

Alectinib presents a formulation problem typical of poorly water-soluble small molecules. The marketed product uses a surfactant and a disintegrant within a conventional capsule system, indicating that wetting and rapid dispersion are relevant performance attributes [1].

Low-solubility management

Potential excipient approaches include:

• Surfactant-enhanced wetting systems
• Amorphous solid dispersions
• Polymer-based precipitation inhibitors
• Lipid or self-emulsifying delivery systems
• Co-processed excipients for direct compression
• Nanomilling or particle-size reduction combined with stabilizing polymers
• Spray-dried or hot-melt-extruded intermediates

A generic developer should not assume that a more technologically advanced formulation will be commercially superior. Alecensa already has an established clinical dose, dosing frequency, food requirement, and safety profile. A formulation that changes exposure under fed or fasted conditions may create a bioequivalence and labeling burden.

Capsule-fill processability

The four-capsule dose per administration creates an immediate opportunity for dosage-form simplification. A tablet, larger-strength capsule, multiparticulate product, or fixed-dose multiunit presentation could reduce pill burden, although each option would require separate development and regulatory justification.

Key process variables include:

• Bulk and tapped density
• Powder flow
• Segregation during filling
• Lubricant sensitivity
• Capsule-shell moisture
• Fill-weight variability
• Dissolution after storage
• Compatibility with high-shear or dry granulation

Magnesium stearate concentration and blending time require particular control because excessive lubrication can delay dissolution. Sodium lauryl sulfate can improve wetting but may introduce compatibility, taste, irritation, or regulatory concerns depending on the dosage form.

What formulations could compete with Alecensa?

The highest-value commercial opportunities are dosage forms that preserve exposure while reducing administration burden or improving manufacturing economics.

Candidate formulation	Potential benefit	Principal development risk
Higher-strength capsule	Fewer capsules per dose	Dose proportionality, fill volume, dissolution
Immediate-release tablet	Lower packaging and manufacturing cost	Compression, disintegration, bioequivalence
Film-coated tablet	Improved handling and identification	Coating process and dissolution control
Amorphous solid dispersion	Improved apparent solubility	Physical stability and recrystallization
Lipid-based formulation	Enhanced solubilization	Food interaction and scale-up
Sprinkle capsule or granules	Administration flexibility	Pediatric and stability requirements
Multiparticulate system	Flexible dose delivery	Content uniformity and manufacturing complexity
Orally disintegrating dosage form	Administration convenience	Taste masking and dose loading
Modified-release product	Reduced dosing frequency	New pharmacokinetic and clinical burden

An immediate-release tablet is the most commercially plausible alternative to the reference capsule. Modified-release and pediatric products offer higher differentiation but face materially greater clinical and regulatory risk.

How should generic manufacturers approach ALECENSA excipient selection?

A generic formulation should begin with the reference product’s critical quality attributes rather than with a preferred excipient platform.

Recommended formulation-control framework

1. Establish the reference product’s dissolution profile across multiple pH conditions.
2. Characterize alectinib hydrochloride particle size, solid state, water content, and morphology.
3. Screen excipients for chemical compatibility and surfactant sensitivity.
4. Measure dissolution under fed and fasted biorelevant conditions.
5. Evaluate the impact of capsule shell moisture and storage humidity.
6. Confirm assay and content uniformity across the full commercial batch size.
7. Compare exposure against the reference product under the FDA’s applicable bioequivalence design.
8. Lock the excipient grade, supplier, and control strategy before pivotal registration batches.

The reference product is administered with food. This makes food-state performance commercially important. A formulation that matches the reference product in standard dissolution but diverges under biorelevant fed conditions may fail to reproduce systemic exposure.

What excipient suppliers can sell into the ALECENSA market?

Excipient suppliers have several potential entry points even before a generic product launches.

High-value supply opportunities

Surfactant suppliers can target sodium lauryl sulfate grades with tighter impurity, particle-size, and flow specifications. Cellulose-derivative suppliers can position hydroxypropyl cellulose and carboxymethylcellulose calcium for low-dose, poorly soluble oncology compounds. Co-processed excipient suppliers can offer platforms designed for direct compression or capsule filling.

Other opportunities include:

• High-purity pharmaceutical lactose
• Low-peroxide excipients for oxidation-sensitive drug substances
• Functionalized polymers for amorphous solid dispersions
• Capsule shells with controlled moisture transmission
• Iron oxide and titanium dioxide color systems
• Ready-to-use capsule-fill blends
• Excipient compatibility and extractables testing
• Continuous manufacturing support
• Analytical methods for dissolution and degradation monitoring

Supplier differentiation will depend on regulatory documentation, global compendial status, change-control discipline, dual sourcing, and demonstrated performance in low-solubility formulations.

What manufacturing and intellectual-property barriers affect ALECENSA substitutes?

The principal manufacturing barrier is not the availability of common excipients. It is the ability to reproduce exposure and dissolution while maintaining robust commercial processing.

Potential barriers include:

• Proprietary alectinib particle engineering
• Salt-form or polymorph control
• Formulation patents covering specific excipient combinations
• Process patents covering granulation or dispersion methods
• Capsule-shell and moisture-barrier patents
• Analytical methods required to distinguish related substances
• Stability data under ICH climatic conditions
• Supplier qualification for critical excipients

A formulation that uses the same excipients as Alecensa does not automatically infringe an originator patent, and a formulation that uses different excipients does not automatically avoid patent risk. The relevant analysis must compare the proposed composition and manufacturing process with issued claims in each target jurisdiction.

What is the FDA exclusivity and Orange Book position for Alecensa?

Alecensa received FDA approval in 2015. Its five-year new chemical entity exclusivity period therefore ran from the original approval date through December 2020, subject to the statutory calculation and any applicable pediatric extension [1][2].

Regulatory issue	Alecensa assessment
New chemical entity exclusivity	Original five-year period has expired
Orphan-drug exclusivity	Not the principal U.S. exclusivity basis for the core NSCLC approval
Pediatric exclusivity	Must be confirmed from current FDA records
Patent listing	Controlled by the current FDA Orange Book entry
Generic filing pathway	ANDA, if the applicant relies on the reference product
505(b)(2) opportunity	Possible only for a materially differentiated product with an appropriate regulatory basis
Biosimilar pathway	Not applicable

The Orange Book remains the controlling source for listed U.S. patents, expiration dates, pediatric extensions, and regulatory exclusivity. Patent listings can change as products receive new indications or additional claims are submitted.

Which companies are challenging Alecensa’s market position?

The competitive threat is primarily from other ALK inhibitors and future alectinib generics, not biosimilars.

Competitor	Company	Competitive relevance
Lorlatinib	Pfizer	Strong CNS penetration and later-line or frontline ALK treatment
Brigatinib	Takeda	Alternative ALK inhibitor with activity in advanced disease
Crizotinib	Pfizer and other suppliers	Earlier-generation ALK inhibitor
Ceritinib	Novartis	Alternative second-generation ALK inhibitor
Ensartinib	Xcovery/partner companies	Potential future competition depending on jurisdiction and approval
Alectinib generics	Multiple potential ANDA sponsors	Direct price competition after regulatory and patent barriers

Alectinib has a strong clinical position because of CNS activity, frontline use, and adjuvant approval. A generic product would compete on price, supply reliability, contracting, and dosage-form convenience rather than on a new clinical mechanism.

When does Alecensa lose commercial exclusivity?

The core FDA chemical exclusivity period has already expired, but commercial exclusivity depends on the remaining patent estate, regulatory exclusivities, litigation outcomes, and timing of an approved generic application.

Paragraph IV challenges

A Paragraph IV ANDA certification can challenge an Orange Book-listed patent before its listed expiration. The originator may bring patent litigation within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework, subject to court decisions and statutory exceptions [3].

The public FDA sources cited here do not establish a definitive launch date for an alectinib generic. A first-filer opportunity, if available, would depend on the ANDA record, the certifications made, litigation, and any settlement terms.

Settlement agreements

Any Alecensa settlement involving an ANDA applicant would need to be assessed for:

• Authorized-generic provisions
• Agreed entry date
• Patent-license scope
• Manufacturing restrictions
• Geographic limitations
• Supply or royalty terms
• FTC review implications

No settlement term should be inferred from the absence of a public launch. Patent litigation, regulatory deficiencies, manufacturing delays, and commercial strategy can produce the same outcome.

What patent protection affects ALECENSA formulation opportunities?

Alecensa’s patent analysis should separate four categories:

1. Composition-of-matter patents covering alectinib or its salt.
2. Solid-state or polymorph patents.
3. Formulation patents covering excipient combinations, dosage forms, or release profiles.
4. Method-of-use patents covering ALK-positive NSCLC treatment, adjuvant use, or dosing regimens.

Formulation developers should conduct a claim chart against each active U.S. and foreign patent family. The analysis should include continuation applications, divisionals, terminal disclaimers, patent-term adjustment, patent-term extension, and jurisdiction-specific claim scope.

Method-of-use patents can be commercially relevant even when a generic seeks approval only for non-patented indications. Label carve-outs and prescriber behavior may affect the practical risk. Adjuvant treatment creates a separate indication-related consideration because its approval occurred later than the initial metastatic indication.

How strong is the Alecensa formulation patent estate?

The commercial strength of the formulation estate depends less on the number of patent documents than on whether issued claims cover a necessary formulation element. A narrow claim to a particular excipient ratio may be avoidable. A broader claim covering a stable oral formulation, a specific solid form, or a required manufacturing process may impose greater design-around pressure.

A strong patent estate would typically contain:

• Claims covering the active salt or solid form
• Multiple continuation families
• Broad formulation claims
• Process claims difficult to design around
• Method claims covering commercially important uses
• Patent-term adjustment or extension
• Protection in major generic markets

An excipient strategy should therefore use independent formulation concepts where technically justified. Simply replacing one diluent or lubricant may not create a meaningful design-around if the patent claims cover the broader dosage form.

What is the revenue exposure from ALECENSA generic entry?

Alecensa revenue exposure is concentrated in oncology markets where ALK testing, treatment guidelines, and long-term therapy support sustained use. Generic entry would likely produce a sharp net-price decline, followed by progressive share erosion as additional suppliers enter.

The most exposed commercial segments are:

• Frontline metastatic ALK-positive NSCLC
• Long-duration maintenance treatment
• Adjuvant treatment after resection
• Markets with automatic generic substitution
• Government and hospital procurement channels

Roche and Genentech can reduce exposure through lifecycle management, supply differentiation, patient-support programs, authorized generic arrangements, or new formulations. These strategies depend on local law and reimbursement structure.

Key Takeaways

• Alecensa is alectinib hydrochloride, marketed in the U.S. as a 150 mg hard capsule.
• The labeled formulation uses lactose monohydrate, hydroxypropyl cellulose, sodium lauryl sulfate, carboxymethylcellulose calcium, and magnesium stearate.
• The most commercially credible formulation opportunity is an immediate-release tablet or higher-strength capsule that reduces the four-capsule burden per dose.
• Alectinib’s solubility, food requirement, solid-state behavior, and dissolution profile are the main technical risks.
• Excipient suppliers can compete through pharmaceutical-grade surfactants, cellulose polymers, low-peroxide materials, co-processed blends, and capsule-shell systems.
• Alecensa’s five-year U.S. new chemical entity exclusivity has expired, but patent and regulatory barriers remain relevant.
• Generic competition follows the ANDA and Paragraph IV framework, not the biosimilar pathway.
• Formulation, solid-state, process, and method-of-use patents must be analyzed separately.
• Adjuvant approval expands the commercial opportunity but may also increase method-of-use and labeling considerations.
• Generic entry timing cannot be determined from initial FDA approval alone. Orange Book listings, patent litigation, certifications, and settlement terms control the practical timeline.

FAQs

Can Alecensa capsules be opened and mixed with food?

The U.S. prescribing information instructs patients to swallow Alecensa capsules with food. It does not establish a general product interchangeability standard for opening capsules and mixing the contents with food [1].

Is sodium lauryl sulfate essential to the Alecensa formulation?

The label identifies sodium lauryl sulfate as an inactive ingredient, but it does not establish that the excipient is indispensable. A generic manufacturer may use an alternative wetting or solubilization strategy if it demonstrates equivalent quality and exposure.

Could alectinib be developed as an amorphous solid dispersion?

Yes. An amorphous solid dispersion is technically plausible for a poorly soluble small molecule, but physical stability, recrystallization, dissolution maintenance, and bioequivalence would require direct demonstration.

Is alectinib suitable for a 505(b)(2) product?

A 505(b)(2) pathway could be relevant to a materially modified dosage form or administration route. A conventional copy of the marketed capsule would generally align more naturally with the ANDA pathway.

Does Alecensa have biosimilar competition?

No. Alectinib is a chemically synthesized small molecule. Competing products would generally be developed as generic drugs rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2024). Alecensa (alectinib) prescribing information. Genentech USA, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Guidance for industry: 180-day exclusivity when multiple ANDA applicants submit substantially complete Paragraph IV certifications. U.S. Department of Health and Human Services.

4. European Medicines Agency. (2024). Alecensa: European public assessment report. European Union.